COVID-19 in Australia
Australia's Zero-COVID strategy saved tens of thousands of lives and kept borders closed for nearly two years before a managed transition to endemicity.
Key Data
| Metric | Data |
| Total confirmed cases | ~11 million |
| Official deaths | ~25,000 |
| Deaths in 2020–2021 | <2,000 (Zero-COVID period) |
| Border reopening | February 21, 2022 |
| Vaccination target | 80% double-vaxxed adults (Doherty modelling) |
| Health authority | Australian Health Protection Principal Committee (AHPPC) |
Zero-COVID and the Geographic Advantage
Australia's island geography provided a natural advantage for Zero-COVID: controlling international entry points was logistically feasible. Australia closed its borders to non-citizens/non-residents on March 20, 2020, and implemented mandatory hotel quarantine for returning citizens. The "hotel quarantine" system varied by state and had occasional failures (the Victoria hotel quarantine leak caused Australia's deadliest 2020 wave — 820 deaths in Victoria in the second wave). Between these outbreaks, Australia achieved near-elimination of community transmission for extended periods — an extraordinary achievement for a population of 25 million.
Doherty Institute Modelling and Transition
Australia's exit from Zero-COVID was guided by mathematical modelling from the Doherty Institute (University of Melbourne), which estimated COVID deaths and hospitalizations at various vaccination coverage levels. The National Plan set 70% and 80% double-vaccinated thresholds as triggers for reopening. Prime Minister Morrison announced the framework in July 2021. When Delta arrived in NSW in June 2021, it ultimately broke through containment — NSW experienced its worst outbreak (over 1,500 cases/day) before vaccination coverage crossed thresholds. Australia transitioned to "living with COVID" in late 2021, managing Omicron with a highly vaccinated population.
Get COVID Alerts
FAQ
Cost-benefit analyses suggest Australia's Zero-COVID strategy prevented an estimated 30,000–40,000 deaths in 2020–2021 compared to a counterfactual of unrestricted spread without vaccines. Economic costs were partially offset by avoiding large healthcare crises. The strategy's limitations emerged with Delta and Omicron, which proved too transmissible to contain indefinitely even with high vaccination. Most public health analysts conclude the strategy was net-beneficial for the period it operated.
Australia initially relied heavily on the AstraZeneca vaccine (domestically produced by CSL) but faced a complication when rare blood clotting events (VITT — vaccine-induced thrombocytopenia and thrombosis) were identified in younger recipients in April 2021. ATAGI (Australian Technical Advisory Group on Immunisation) recommended Pfizer as preferred for under-50s, causing vaccine hesitancy and rollout delays. Australia ultimately transitioned to Pfizer/Moderna for younger cohorts while AstraZeneca remained available for older adults.
Sources: Australian Government COVID-19 dashboard; Doherty Institute modelling reports; Lancet (Bennett et al. Australia Zero-COVID analysis); AHPPC statements.
Related: COVID-19 overview · Japan COVID · South Korea COVID